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Among new biological markers that could become useful prognostic factors for lung carcinoma, Ki-67 is a nuclear protein involved in
cell proliferation regulation. Some studies have suggested an association between Ki-67 and poor survival in lung cancer patients. In
order to clarify this point, we have performed a systematic review of the literature, using the methodology already described by our
Group, the European Lung Cancer Working Party. In total, 37 studies, including 3983 patients, were found to be eligible. In total, 49%
of the patients were considered as having a tumour positive for the expression of Ki-67 according to the authors cutoff. In all, 29 of
the studies dealt with non-small-cell lung carcinoma (NSCLC), one with small-cell carcinoma (SCLC), two with carcinoid tumours and
five with any histology. In terms of survival results, Ki-67 was a bad prognosis factor for survival in 15 studies while it was not in 22. As
there was no statistical difference in quality scores between the significant and nonsignificant studies evaluable for the meta-analysis,
we were allowed to aggregate the survival results. The combined hazard ratio for NSCLC, calculated using a random-effects model
was 1.56 (95% CI: 1.30–1.87), showing a worse survival when Ki-67 expression is increased. In conclusion, our meta-analysis shows
that the expression of Ki-67 is a factor of poor prognosis for survival in NSCLC.
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Molecular biology by the analysis and characterisation of proteins
and genes involved in cancer development, could improve the
knowledge of prognostic factors. By using the methodology of
systematic reviews of the literature with meta-analyses, our Group
has shown a prognostic role for several biological factors in lung
cancer: p53 (Steels et al, 2001), Bcl-2 (Martin et al, 2003), vascular
endothelial growth factor (VEGF) (Delmotte et al, 2002), epidermal
growth factor receptor (EGFR) (Meert et al, 2002a), Neu (Meert
et al, 2003) and microvessel density (Meert et al, 2002b).
Another field to explore by a meta-analysis is tumour
proliferation, for example by the expression of Ki-67. The
proliferation rate has been related to survival prediction (Murray
and Kirschner, 1989; Pardee, 1989) and tumour cell kinetics
studies have indicated a relationship between high cell prolifera-
tion rates and tumour aggressiveness (Tubiana and Courdi, 1989).
Ki-67, a nonhistone protein, is a DNA-binding nuclear protein
expressed throughout the cell cycle in proliferating cells, but not in
quiescent (G0) cells. It has been used to distinguish growing from
non growing cells (Seigneurin and Guillaud, 1991; Guinebretiere
and Sabourin, 1997; Scholzen and Gerdes, 2000), although its exact
function remains unclear.
Despite a large number of studies performed in lung cancer
patients, the prognostic value of Ki-67 for survival remains
controversial. Therefore, we performed a systematic review of
the literature with meta-analysis to assess the prognostic value of
its overexpression for survival.
MATERIALS AND METHODS
Publication selection
To be eligible for this systematic review, studies had to deal with
lung cancer only, to evaluate the relationship between Ki-67 status
and survival, to measure Ki-67 expression in primary tumour and
to be published as a full paper in the English or French language
literature. Abstracts were excluded because of insufficient data.
Articles were identified by an electronic search on Medline using
the following keywords: ‘lung neoplasm’, ‘lung adenocarcinoma’,
‘NSCLC’, ‘SCLC’, ‘Ki-67’, ‘Ki67’, ‘MIB-1’, ‘proliferative index’,
‘proliferative activity’, ‘mitotic index’, ‘mitotic count’. The
bibliographies reported in all the identified studies were used for
completion of the studies search. When authors reported, in
several publications, on the same patients population, only the
most recent or complete study was included into the analysis, in
order to avoid overlapping between cohorts. The search ended on
December 2002.
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In order to assess the study methodology, eight investigators (six
physicians, one biostatistician and one biologist) read each
publication independently, and scored them using the European
Lung Cancer Working Party (ELCWP) scale. This scoring system
has been previously described (Steels et al, 2001). The scores
proposed by each reader were compared and a consensus value for
each item was reached. The participation of many readers
warranted a correct interpretation of the articles.
The score evaluated various aspects of methodology, grouped
into four main categories: the scientific design, the description of
the laboratory methods used to identify the presence of Ki-67
(protein, DNA/RNA or antibodies against Ki-67), the generalisa-
bility of results and the analysis of the study data. Each category
had a maximum score of 10 points, and the overall maximal
theoretical score was 40 points. When an item was not applicable,
its value was not taken into account in the total of the concerned
category. The final scores were expressed as percentages, higher
values reflecting better quality methodology.
Studies included in the systematic review were called ‘eligi-
ble’ and those providing sufficient data for the meta-analysis
‘evaluable’.
Statistical methods
A study was considered as significant if the P-value for the
statistical test comparing the survival distributions between the
groups with and without Ki-67 expression, was o0.05. A study was
classed as ‘positive’ when Ki-67 expression was identified as a good
prognosis factor for survival in univariate analysis. A study was
called ‘negative’ if the Ki-67 overexpression was associated with a
significant detrimental effect on survival. Finally, a study was
called ‘not significant’ if no difference between groups expressing
or not Ki-67 was detected.
The association between the score measurements or between a
score measurement treated as a continuous variable and another
continuous variable was measured by the Spearman rank
correlation coefficient. The comparison between score measure-
ment according to the value of a discrete variable was made by
nonparametric Mann–Whitney (for dichotomic variables) or
Kruskal–Wallis (for nominal variables with multiple classes) tests.
For the quantitative aggregation of the survival results, the
impact of Ki-67 expression on survival was measured by hazard
ratio (HR). For each study, this HR was estimated by a method that
depended on the results provided in the publication. The most
accurate method was to retrieve the estimated HR and its standard
error using two of the following parameters: the HR point estimate,
the logrank statistic or its P-value, the O–E statistic (difference
between numbers of observed and expected events) or its variance.
If those data were not available, we looked for the total number of
events, the number of patients at risk in each group and the
logrank statistic or its P-value, allowing calculation of an
approximation of the HR estimate. Finally, if the only useful data
were in the form of graphical representations of the survival
distributions, we extracted from them survival rates at specified
times in order to reconstruct the HR estimate and its variance,
with the assumption that the rate of patients censored was constant
during the study follow-up (Parmar et al, 1998). Three indepen-
dent persons read the curves to reduce the imprecision in the
reading variations. If authors reported survival of three or more
groups (for example, using several cutoff values for percentage of
protein present in the nucleus), we pooled the results in order to
make a comparison between two groups feasible.
The individual HR estimated were combined into an overall HR
using the method published by Peto (Yusuf et al, 1985). We tested
the homogeneity of the analysis by performing w
2 tests for
heterogeneity. If the assumption of homogeneity had to be
rejected, we used a random-effect model in place of a fixed-effect
model. By convention, an observed HR41 implied a worse
survival for the group with positive Ki-67 expression. This impact
of Ki-67 on survival was considered as statistically significant if the
95% confidence interval (CI) for the overall HR did not overlap 1.
For each study, the survival of the overall patients population
was analysed, when available. If not, the HR was estimated on
subgroups. If survival was reported separately for particular
subgroups, these results were treated in the meta-analysis of the
corresponding subgroups.
RESULTS
Studies characteristics
In total, 42 studies published between 1991 and 2002 were selected
for this systematic review (Tungekar et al, 1991; Hayashi et al,
1993; Pence et al, 1993; Kawai et al, 1994; Costes et al, 1995;
Giaccone et al, 1995; Harpole, Jr et al, 1995, 1996; Bohm et al, 1996;
Fontanini et al, 1996; Giatromanolaki et al, 1996a,b; Pujol et al,
1996; Bellotti et al, 1997; Ishida et al, 1997; Komaki et al, 1998;
Mehdi et al, 1998; Soomro et al, 1998; D’Amico et al, 1999, 2000;
Dazzi et al, 1999; Dingemans et al, 1999, 2001; Santinelli et al,
1999; Cagini et al, 2000; Carvalho et al, 2000; Demarchi et al,
2000; Hommura et al, 2000; Nguyen et al, 2000; Shiba et al, 2000,
2001; van de Vaart et al, 2000; Ferreira et al, 2001; Hayashi et al,
2001; Pelosi et al, 2001; Puglisi et al, 2001, 2002; Ramnath et al,
2001; Tsoli et al, 2001; Carbognani et al, 2002; Minami et al, 2002;
Rigau et al, 2002). Five were excluded because an identical patients
cohort was used in another selected publication (references
excluded/included: D’Amico et al, 2000/1999; Giatromanolaki
et al, 1996a/1996b; Harpole Jr. et al, 1995/1996; Puglisi et al,
2002/2001; Shiba et al, 2001/2000).
The main features of the 37 studies eligible for the systematic
review are shown in Table 1. A total of 29 studies dealt with NSCLC
alone, while SCLC and carcinoid tumours were studied in 1 and
2 studies respectively. Five included tumours of any histology.
Table 1 Main characteristics and results of the eligible studies
All studies
NSCLC
SCLC
Carcinoid
tumours
Any histology
any stage Any stage (I–IV)
Locoregional
(I–II)
Surgical treatment
(I–III)
Total S Total S Total S Total S Total S Total S Total S
Number of
studies
37 (20) 15 (10) 10 (5) 4 (4) 8 (5) 3 (2) 11 (6) 3 (2) 1 (1) 1 (1) 2 (1) 2 (1) 5 (2) 2 (0)
NSCLC¼non-small-cell lung cancer; SCLC¼small-cell lung cancer; S¼number of studies identifying Ki-67 positivity as a statistically significant prognostic factor; ()¼number of
studies evaluable for meta-analysis.
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subtypes (n¼25) or adenocarcinoma alone (n¼4). Of the 29
NSCLC studies, 11 dealt with patients treated by surgery (stages I-
IIIB); eight were performed in surgical stages (stages I–II), while
10 dealt with all stages (I–IV).
Immunohistochemistry (IHC) was the only technique used to
detect the expression of Ki-67 protein. Various antibodies were
used to assess Ki-67 expression: the clone MIB-1 in 68% of the
studies and the Dako clone in 16%; the nature of the antibody was
not described in 16%.
Of the 37 studies eligible for the systematic review, 17 provided
insufficient data to perform a quantitative aggregation. The
reasons for not including these studies in the meta-analysis were
the following: no survival curve shown (n¼2) (Bellotti et al, 1997;
Carvalho et al, 2000); no P-value, HR or CI reported (n¼8) (Kawai
et al, 1994; Giatromanolaki et al, 1996a; Bellotti et al, 1997; Komaki
et al, 1998; Santinelli et al, 1999; Hayashi et al, 2001; Ramnath et al,
2001; Carbognani et al, 2002); distribution of Ki-67 status not
reported (n¼11) (Tungekar et al, 1991; Kawai et al, 1994;
Giaccone et al, 1995; Bellotti et al, 1997; Komaki et al, 1998;
Soomro et al, 1998; Dazzi et al, 1999; Dingemans et al, 2001;
Ferreira et al, 2001; Pelosi et al, 2001; Rigau et al, 2002).
Studies results
As shown in Table 1, 15 of the 37 studies (40.5%). were negative
showing Ki-67 expression as a bad prognostic factor for survival
(10 of these 15 studies were evaluable for meta-analysis). The 22
remaining studies were not significant.
Out of the 29 studies performed in NSCLC, 10 (34.5%) were
negative, including eight studies evaluable for meta-analysis. The
studies related to SCLC and one of the two studies dealing with
carcinoid tumours were negative.
A total of 3983 patients were included in the eligible studies. Ki-
67 expression was clearly described for 2437 patients (61.2%): 49%
(ranging from 10 to 78% according to the study) had a tumour
with a positive immunostaining according to the authors cutoff
(range 1–60%).
Quality assessment
Before attempting to aggregate the results of the individual studies,
a qualitative assessment of each study was performed. The global
quality assessment score, ranged between 21.2 and 84.1%, with a
median of 50.6% (Table 2A). The design subscores had the lowest
values. The most poorly described items (o30% of the maximum)
were the a priori estimate of sample size required to conduct the
study, the reproducibility control test between the experimenters,
the initial disease work-up description and the number of
unassessable samples with the reasons for their exclusion.
Weak and statistically nonsignificant correlations between the
global score and either the number of patients included in the
study (Spearman’s correlation coefficient r¼0.28, P¼0.09) or the
date of publication (Spearman’s correlation coefficient r¼0.12,
P¼0.48) were observed.
No statistically significant difference was found between the 15
significant and the 22 nonsignificant studies for the global score
(median 52.5 in comparison to 49.2%, P¼0.42), nor for the four
subgroups scores.
Table 2 Methodological assessment by the ELCWP score, according to studies characteristics
Global score (%) Design (/10) Laboratory methodology (/10) Generalisabilty (/10) Results analysis (/10)
(A) All studies (n¼37)
All studies 50.6 4.0 5 6.7 6.2
Patient number
r Spearman 0.28 0.25 0.26 0.44  0.005
P-value 0.09 0.13 0.12 0.007 0.97
Date of publication
r Spearman 0.12 0.09 0.13 0.11 0.16
P-value 0.48 0.59 0.44 0.54 0.36
Evaluable for the MA
Yes (n¼20) 60.7 5.0 5.7 6.7 7.5
No (n¼17) 45.8 3.0 4.3 5.8 5.0
P-value 0.002 0.009 0.009 0.57 0.004
Significant results for survival
Yes (n¼15) 52.5 4.0 5.0 6.7 6.2
No (n¼22) 49.2 3.5 5.0 6.2 5.0
P-value 0.42 0.30 0.82 0.44 0.47
(B) Studies evaluable for meta-analysis (n¼20)
All studies 60.8 5.0 5.7 6.7 7.5
Patient number 0.59
r Spearman 0.45 0.31 0.27 0.57 0.80
P-value 0.04 0.18 0.24 0.009
Date of publication
r Spearman 0.20  0.09 0.31 0.23 0.28
P-value 0.38 0.71 0.19 0.32 0.22
Significant results for survival
Yes (n¼10) 58.4 4.5 5.4 6.7 7.5
No (n¼10) 68.0 5.5 6.1 6.2 6.9
P-value 0.54 0.34 0.40 0.88 0.57
Scale distributions are summarised by median value. MA¼meta-analysis. The P-values in bold are significant.
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and nonevaluable studies for meta-analysis (median overall score:
60.7 vs 45.8%, P¼0.002).
Scores of the 20 studies evaluable for the meta-analysis are
reported in Table 2B. The overall quality score ranged between 21.2
and 84.1%, with a median of 60.8%. There was a significant
correlation between the global score and the number of patients
included in the study (Spearman’s correlation coefficient r¼0.45,
P¼0.04), with better scores in case of higher number of patients.
The most poorly described items were similar to the all eligible
studies. There was no significant difference between significant
and nonsignificant studies for the global score with a median
overall quality score of 58.4 and 68.0% respectively (P¼0.54).
Meta-analysis
The absence of any significant methodological qualitative differ-
ence between significant and nonsignificant studies led us to
perform quantitative aggregations of the survival data of the 2233
patients included in the 20 studies. Only subgroup analyses were
performed due to the heterogeneity of the studies: heterogeneity
related to different histological types (NSCLC, SCLC or carcinoid),
stages (localised, locoregional or extensive) or treatments. The
subgroups analysed were defined according to histology and extent
of the disease. The studies related to carcinoid tumours (n¼1),
small-cell-lung cancers (n¼1) and the two evaluable studies
related to any histology were not included in the present analysis,
because their aggregation with other groups was not meaningful.
The hazard ratios were retrieved by one of the three methods
reported in the Materials and Methods section. No study reported
the summary statistics necessary to directly estimate the HR, but in
four studies, the authors showed the individual data allowing us to
make a direct estimation of the HR. In eight studies, the HR was
approximated using the total number of events and the log-rank
statistic or its P-value. For the eight remaining studies, the HR was
extrapolated from the graphical representation of the estimated
survival distributions.
The NSCLC subgroup included 16 studies with 1863 patients.
One study (Hayashi et al, 1993) was divided into two subgroups.
The aggregated survival data showed a poor survival prognosis in
case of Ki-67 positivity (HR¼1.55, 95% CI 1.34–1.78). There was
no detectable heterogeneity between studies (P¼0.12) but, as the
w
2 test for heterogeneity was lacking from statistical power, we also
used a random-effects model, with a result that was still
statistically significant (HR 1.56, 95% CI 1.30–1.87) (Figure 1).
We also analysed the data according to histology subtypes and
tumour stage (Table 3). For all the subgroups except stage I–II, the
aggregation produced a statistically significant HR. The use of a
random-effects model provided similar results.
DISCUSSION
The present systematic review shows that the expression of Ki-67
in resected non-small-cell lung cancer is a poor prognostic factor
for survival. We cannot extrapolate our results to metastatic
NSCLC, to small cell lung cancer or to carcinoid tumours, because
of a lack of adequate studies dealing with these specific
presentations or histologies.
To perform the meta-analysis, we used the same methodology
than in our previous systematic reviews (Meert et al, 1999,
2002a,b; Mascaux et al, 2000; Sculier et al, 2001; Steels et al, 2001;
Martin et al, 2003). The absence of statistically significant
difference in quality scores between significant and nonsignificant
publications allowed us to perform a quantitative aggregation of
the individual studies results. Nevertheless, our approach does not
eliminate all potential biases.
The review was restricted to articles published in English or
French languages because other languages such as Japanese (Wang
et al, 1997a,b; Klein et al, 2000; Kayser et al, 2001; Sekine and
Fujisawa, 2003) were not accessible to the readers. This selection
could favour the positive studies that are more often published in
English while the negative ones tend to be more often published in
native languages (Egger et al, 1997). Moreover, our review took
into account only fully published studies. We did not look for
unpublished studies and abstracts because our methodology
required data only in available in full publications order to
perform methodology assessment and meta-analysis.
Meta-analysis based on individual data is considered by some
authors as a gold standard (Stewart and Parmar, 1993). Systematic
Cagini, 2000
D'amico,1999
Demarchi, 2000
Fontanini,1996
Harpole,1995
Hayashi  Adeno,1993
Hayashi  Squamous,1993
Hommura, 2000
Ishida,1997
Mehdi,1998
Minami, 2002
Nguyen, 2000
Pence,1993
Puglisi, 2001
Shiba, 2000
Tsoli, 2001
0.0 2.5 5.0 7.5 10.0
van de Vaart, 2000
Figure 1 Results of the meta-analysis with all NSCLC studies. A hazard
ratio (HR)41 implies a worse survival for the group with no increased Ki-
67 expression. The square size is proportional to the number of patients
included in each study. The centre of the lozenge gives the combined HR
for the meta-analysis and its extremities the 95% confidence interval.
Table 3 HR value for NSCLC subgroups according to histology subtypes and stages
Subgroup Studies Patients Fixed effect HR (95% CI) Heterogeneity test Ramdom effect HR (95% CI)
Adenocarcinoma n¼4 258 2.45 (1.66–3.64) P¼0.26
Nonsquamous carcinoma n¼3 158 2.47 (1.32–4.57) P¼0.90
Stage I n¼4 783 1.56 (1.26–1.93) P¼0.17
Stage I–II n¼4 437 1.16 (0.82–1.66) P¼0.21
Stage I–III n¼6 533 1.79 (1.40–2.28) P¼0.04 1.82 (1.26–2.64)
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of individual patients data. The first approach is based on fully
published data and provides an exhaustive and critical analysis on
the topic with an adequate methodology based on the criteria of
Mulrow (1987). The second approach is, in fact, a new study taking
into account all performed studies on the topic, published or not,
requiring individual data updated by the investigators and is much
more time-consuming. Nevertheless, our approach based on the
literature provides similar results as shown by our meta-analysis
on the role of prophylactic cerebral irradiation in small-cell lung
cancer (Meert et al, 2001), where the results based on published
data were the same as those found in the meta-analysis based on
individual patients data (Auperin et al, 1999).
Another possible source of confusion is the use of the same
cohort of patients in different publications. It might be difficult to
avoid inclusion of some patients more than once in the meta-
analysis, although publications clearly based on the analyses of the
same patients cohorts were excluded. We have assumed that
authors have been honest and have not reported the results from
the same cohort of patients without mentioning it in their
publications.
Studies assessing Ki-67 in lung cancer patient are heteroge-
neous. For reasons of homogeneity, our meta-analysis was
performed only with studies dealing with NSCLC histology. By
consequence, the Pujol study (Pujol et al, 1996) was not included
because a few patients with SCLC were incorporated in the series.
Nevertheless, similar results were obtained if this study was
included but the heterogeneity increased. We restricted the
analyses to the histological subtypes or tumour stages for which
we had a sufficient number of studies. It was not possible, on the
basis of published data, to adjust our results in a multivariate
analysis although the usefulness of a new prognostic factor
requires an independent prognostic value.
In total, 17 studies were excluded from the meta-analysis due to
lack of the data necessary for aggregation. There is therefore a
publication bias. These studies were not all statistically significant.
It is known that nonsignificant studies are less frequently
published or, if they are, with less detailed results, making them
less assessable.
Another potential source of bias is related to the method for
extrapolating the HR. If the authors did not report the individual
HR together with its variance, we calculated it from the survival
comparison statistic and its variance whenever possible. If not, we
extrapolated it from the survival curves using several time points
during follow-up for reading the corresponding survival rates,
assuming that censored observations were uniformly distributed.
This methodology is described in (Puglisi et al, 1998). Reading the
survival rates on the graphical representation of the survival curves
was performed independently by three of the authors, but this
strategy does not eliminate completely inaccuracy in the extracted
survival rates. Consequently, the estimated HR might be less
reliable than when obtained from published statistics. Further-
more, we determined quite arbitrarily time intervals for reading
survival rates on the curves, but we are not aware about any
accepted methodology for the choice of the time intervals and their
number. However, we compared our estimated HR and its
statistical significance with the results published in each individual
method and we did not identify any major contradiction between
our results and the results available in the papers.
The techniques used to identify the expression of Ki-67 can also
be a potential source of bias. Immunohistochemistry used to reveal
Ki-67 protein was not always performed with the same antibody:
clone Mib-1 in the majority of the studies (Costes et al, 1995; Bohm
et al, 1996; Fontanini et al, 1996; Bellotti et al, 1997; Ishida et al,
1997; Komaki et al, 1998; Dazzi et al, 1999; Dingemans et al, 1999,
2001; Santinelli et al, 1999; Cagini et al, 2000; Demarchi et al, 2000;
Hommura et al, 2000; Nguyen et al, 2000; Shiba et al, 2000, 2001;
van de Vaart et al, 2000; Ferreira et al, 2001; Hayashi et al, 2001;
Puglisi et al, 2001, 2002; Ramnath et al, 2001; Tsoli et al, 2001;
Minami et al, 2002; Rigau et al, 2002), antibodies coming from a
firm selling several clones but without mention of the clone used
(Hayashi et al, 1993; Pence et al, 1993; Kawai et al, 1994; Giaccone
et al, 1995; Pujol et al, 1996; Mehdi et al, 1998; Soomro et al, 1998;
Carbognani et al, 2002); any mention of the antibodies used
(Tungekar et al, 1991; Harpole Jr et al, 1995, 1996; Giatromanolaki
et al, 1996a,b; D’Amico et al, 1999, 2000; Carvalho et al,
2000;Pelosi et al, 2001). Two recent comparisons of four Ki-67
antibodies showed that there were considerable differences in the
mean percentage of immunoreactive nuclei (Lindboe and Torp,
2002; Lindboe et al, 2003). According to these studies, the clone
MIB-1 appears to have a higher sensitivity for detecting the Ki-67
antigen than other antibodies and it also gives the best visual
staining. The antibodies concentration is also a factor having an
influence on the staining result because of the intensity is
correlated to the antibody concentration used. This aspect of the
immunohistochemistry does not seem important for some authors
because they do not specify the antibodies concentration
(Tungekar et al, 1991; Hayashi et al, 1993; Costes et al, 1995;
Harpole Jr et al, 1995, 1996; Giatromanolaki et al, 1996a,b; Pujol
et al, 1996; D’Amico et al, 1999, 2000; Dazzi et al, 1999; Santinelli
et al, 1999; Nguyen et al, 2000; Shiba et al, 2000, 2001; Pelosi et al,
2001; Carbognani et al, 2002; Minami et al, 2002). Sometimes the
immunohistochemical technique was performed without prior
reaction for unmasked epitope on fixed tissue. Moreover, the
cutoff defining a tumour with a Ki-67 positive staining is often
arbitrary and varies according to the investigators, from a few
percent to more than 50%. The use of different cutoff points for
IHC is of critical importance, as shown by Lee et al (1995). Some
investigators selected the cutoff point based on the minimum P-
value approach, which can lead to seriously biased conclusions
(Altman et al, 1994). If a chosen cutoff is often arbitrary, selection
according to the median value of expression levels provides a more
standardised approach to prognostic factors, although it may lead
to some loss of information (Altman et al, 1994). In breast cancer,
in a recent study, Spyratos et al (2002) compare Ki-67 scores with
other classic factors measuring the proliferation rate, namely the
mitotic index, which is a component of histologic grading system.
They used five different Ki-67 cutoffs to define the most
appropriate cutoff for distinguishing between tumours with low
and high proliferation rates. These authors observed that with a
Ki-67 cutoff of 10%, few tumours with low proliferation were
misclassified. Conversely, a Ki-67 cutoff of 25% acceptably
identified highly proliferative tumours. According to Spyratos
et al (2002), the choice of cutoff depends on the clinical objective:
if Ki-67 is used to exlude patients with slowly proliferating
tumours from chemotherapeutic protocols, a cutoff of 10% will
help to ovoid overtreatment. In contrast, if Ki-67 is used to identify
patients sensitive to chemotherapy protocols, it is preferable to set
the cutoff at 25%. The Ki-67 index should be combined with some
other routinely used proliferative markers such as the mitotic
index. In consequence, an optimal threshold still needs to be
defined for Ki-67 and validate for lung cancer.
Cell division kinetics is an important predictor of the clinical
outcome of various carcinoma. Cellular proliferation can be
measured using a variety of methods. Mitotic indices have been
widely used as part of various tumour grading methods (Elston
and Ellis, 1993; Silverberg, 2000; Hilska et al, 2002). The mitotic
index is a rapid an cost-effective tool for estimating tumour cell
proliferation, and reasonable reproducibility can be achieved with
a strictly standardized methodology (Elston and Ellis, 1993).
Immunohistochemical determination of proliferation indices is an
expanding area of research, based on detection of antigens
presents during cell proliferation (Gerdes et al, 1991; Scholzen
and Gerdes, 2000) such as Ki-67 with clone Mib-1. For many
authors (Rudolph et al, 1998; Lehr et al, 1999; Spyratos et al, 2002),
high Ki-67 clone Mib-1 was associated with a high mitotic index.
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were always the most discriminant variable. In clinical trials, Ki-67
clone Mib-1 could be used in conjunction with the mitotic index to
ensure correct tumour classification on the basis of proliferative
potential.
A few studies suggest a predictive role for Ki-67, in that an
individual patient’s tumour might be treated in a specific way based
on its degree of Ki-67 expression. Tumour cell proliferation after
hormonal treatment is a prognostic factor of recurrence in prostate
cancer treated with neoadjuvant luteinizing hormone-releasing
hormone treatment and radical prostatectomy (Ahlgren et al, 1999).
The same results were obtained with patient treated by external beam
radiotherapy (Khoo et al, 1999). Highly proliferative breast tumours
are associated with shorter patient survival. Studies have suggested
that highly proliferative tumours show increased sensitivity to
neoadjuvant (Remvikos et al, 1989) and adjuvant chemotherapy
(Simpson et al, 2000), regardless of the impact of such treatment on
patient survival. In contrast, the rationale of chemotherapy for slowly
proliferating tumours is controversial (Wenger and Clark, 1998).
Information on cell proliferation may be a useful adjunct to
histologically based tumour classification in the understanding of
tumour behaviour. In a variety of malignant neoplasms, significant
correlations have been found between proliferative activity and
metastatic potential, recurrence or overall prognosis (Hall and
Levison, 1990). In our systematic review with meta-analysis,
patients with Ki-67 positive tumours had shorter survival than
those with Ki-67 negative tumours. The mechanism underlying the
effect of Ki-67 protein expression on tumour progression as
prognosis remains essentially uncertain. However, it has to be
considered that positivity for the Ki-67 antigen may reflect the
ability of a cell to continue to proliferate after the time of tumour
resection. In fact, a cell would be positive as long as it is going to
divide but the term going to divide refers not to the actual state of
the cell but to an event in the future. The cell must make the final
decision whether to divide at some time point during the cell cycle.
In practice, these considerations should not be regarded as
drawbacks. As the Ki-67 index (percentage of cells stained positive
for the Ki-67 antigen) is directly based on a physiological
parameter involved in cell proliferation, it may give an even better
insight into the growth characteristics of a tumour, its suscept-
ibility to certain drugs, and to the outcome of a patient that the
estimation of the growth fraction. It is also evident that estimating
the growth fraction alone is not sufficient to describe the tumour
growth. The growth fraction (and the Ki-67 labelling index) relates
only to the number (or fraction) of proliferative cells but not to the
time needed for the completion of an intermitotic cycle. In other
words, the estimation of the growth fraction gives information
only about the state but not about the rate of proliferation;
therefore, an additional marker would be helpful to assess this
parameter. In the future, multiparameter analysis may provide a
better means for analysing cell proliferation and tumour growth.
This may not only improve the prognostic value but also be a
prerequisite for choosing the appropriate type of therapy for each
individual case.
In conclusion, our systematic review of the literature shows that
expression of Ki-67 in patients with stages I–III NSCLC is a poor
prognostic factor for survival. Our results were based on the
aggregation of data obtained in univariate survival analyses
performed in retrospective studies. In order to become a useful
prognostic factor in the clinical practice, a standardisation of the
immunohistochemistry technique is needed, particularly concern-
ing the positivity threshold. In addition, the present results need to
be confirmed by an adequately designed prospective study with an
appropriate multivariate analysis taking into account the classical
well-defined prognostic factors for survival in lung cancer patients.
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